LubomirSokolMD
Hematology • Tampa, FLHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Physician
Overview of Dr. Sokol
Dr. Lubomir Sokol is a hematologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. He received his medical degree from University Karlovy, Lek Fak Ii and has been in practice 36 years. Dr. Sokol accepts several types of health insurance, listed below. He is one of 45 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 6 doctors at Tampa General Hospital who specialize in Hematology. He has more than 100 publications and over 500 citings.
Office
12902 USF Magnolia Drive
Tampa, FL 33612Fax+1 813-745-5959
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2000 - 2002
LSU Health Sciences Center/University Hospital and Clinics (Lafayette)Residency, Internal Medicine, 1997 - 1999- University Karlovy, Lek Fak IiClass of 1981
Certifications & Licensure
FL State Medical License 2000 - 2026
LA State Medical License 1999 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2014
- America's Top Doctors for Cancer Castle Connolly, 2011-2013
Clinical Trials
- Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2008 Jul 09
- Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Start of enrollment: 2012 Mar 30
- Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly Start of enrollment: 2013 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 68 citationsPrimary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelinesNeha Mehta-Shah, Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Jeffrey A. Barnes
Journal of the National Comprehensive Cancer Network. 2020-05-01 - 16 citationsExcimer laser in the treatment of mycosis fungoidesDarcie Deaver, Ashley Cauthen, George Cohen, Lubomir Sokol, Frank Glass
Journal of the American Academy of Dermatology. 2014-06-01 - 34 citationsBrentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.Jeremy S. Abramson, Jon E. Arnason, Ann S. LaCasce, Robert A. Redd, Jeffrey A. Barnes
Blood. 2019-08-15
Journal Articles
- Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyMichael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
Abstracts/Posters
- Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt ExperienceLubomir Sokol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Bnz-1, a Selective _-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: ...Lubomir Sokol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Blockade of IL-15 Utilizing Bnz-1, a Selective _-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemi...Lubomir Sokol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018
Press Mentions
Hospitalization Outcomes in Patients with CTCL: A Multi-Center StudyMarch 26th, 2022- Poster Awards Announced Ahead of 2022 Meeting in BostonMarch 7th, 2022
- Potential New Drug Target to Treat Cutaneous T Cell LymphomaDecember 21st, 2020
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOCoventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
